Journal Articles

he genetic and epigenetic landscape for CNS drug discovery targeting cross-diagnostic behavioral domains

August 05, 2014

The genetic and epigenetic landscape for CNS drug discovery targeting cross-diagnostic behavioral domains. Eur J Pharmacol. 2014 Aug 5 de Mooij-van Malsen A1, Pjetri E2, Kas MJ3.

  • 1Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; Institute of Physiology, CAU Kiel, Germany.
  • 2Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands; UNC Chapel Hill- Nutrition Research Institute North Carolina Research Campus, Kannapolis, NC 28081, USA.
  • 3Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands. Electronic address: m.j.h.kas@umcutrecht.nl.

Abstract

Animal studies play a central role in the identification and testing of novel drugs for CNS disorders. In his longstanding career, Berend Olivier has significantly contributed to CNS drug discovery by applying and supporting novel views and methodologies in the fields of behavioural neuroscience, pharmacology, and (epi-) genetics. Here we review and put forward some of these integrated approaches that have led to a productive collaboration and new insights into the genetic and epigenetic regulation of neurobehavioural traits related to psychiatric disorders.

Copyright © 2014. Published by Elsevier B.V.

Comments are closed.

Connect With Us